Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 26, 2011

BaseClear Joins Roche NimbleGen’s Certified Service Provider Program

  • BaseClear has become the first company in Europe and the second provider worldwide to win certification under Roche NimbleGen’s certified service provider program for use of the NimbleGen SeqCap EZ Library (solution phase) workflow for next-generation sequencing.

    The company will process customer samples in its lab in Leiden, The Netherlands, using NImbelGen's SeqCap EZ Exome sequence-capture technology, version 2.0 products. BaseClear offers services for DNA-based research, quality assurance, and forensics.

    Roche NimbleGen's first CSP in the U.S., Ambry Genetics, won the designation last September as a supplier of NimbleGen's SeqCap EZ Exome. Ambry, a CAP-accredited, CLIA-certified commercial clinical laboratory, earlier this month became the first CSP to become certified on all Roche NimbleGen applications including comparative genomic hybridization (CGH), chromatin immunoprecipiation-on-chip (ChIP-chip), DNA methylation, and gene expression products.

    Atlas Biolabs qualified last month as the first CSP in Germany for the Roche NimbleGen SeqCap EZ genomic enrichment technology. In the U.K., NewGene late last year won CSP certification for services related to SeqCap EZ arrays with sequencing on the Genome Sequencer FLX System from 454 Life Sciences. In addition, NewGene will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture Array workflow optimized for 454 GS FLX Titanium Series sequencing.

    Also last year, CapitalBio won CSP certification to process customer samples for NimbleGen Gene Expression, CGH/Copy Number Variation (CGH/CNV), and DNA Methylation services in their lab in Beijing and was the first NimbleGen CSP in Asia to implement the MS 200 Microarray Scanner into their array workflow for high-resolution scanning.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »